Buscar resultados de ensayos clínicos
Chronic Inflammatory Demyelinating Polyneuropathy - 26 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2012-06-19 Intervenciones:
|
Completed |
Nombre del estudio: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2004-12-15 Intervenciones: Drug: Interferon Beta-1a |
Completed |
Nombre del estudio: Effect of Resistance and Aerobic Exercise in CIDP or MMN Condición:
|
Withdrawn |
Nombre del estudio: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Condición: Chronic Inflammatory Demyelinating Polyneuropathy Fecha: 2015-08-30 Intervenciones: Drug: H.P. Acthar® Gel Other Names:
|
Not yet recruiting |
Nombre del estudio: Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2016-08-29 Intervenciones:
|
Completed |
Nombre del estudio: MRI in Diagnosing and Monitoring CIDP Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2013-12-06 |
Recruiting |
Nombre del estudio: Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2014-11-13 Intervenciones: Drug: I10E Patients who meet all eligibility criteria will |
Recruiting |
Nombre del estudio: Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2014-12-11 Intervenciones: Drug: I10E Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 4 |
Recruiting |
Nombre del estudio: Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2016-11-02 Intervenciones: Biological: HYQVIA Other Names:
|
Recruiting |
Nombre del estudio: Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Condición: Chronic Inflammatory Demyelinating Polyradiculoneuropathy Fecha: 2015-09-11 Intervenciones:
|